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 ABSTRACT | Objective: To analyze the difference between p16inka immunostaining in normal epithelium, two benign HPV-related 
lesions (papilloma and condyloma acuminatum), and one malignant HPV-related lesion (oropharynx carcinoma). Meth-
ods: Five normal oral mucosas, fifteen papilloma, fifteen condyloma acuminatum, and fifteen HPV-positive orophar-
ynx squamous cell carcinoma were included in this study. The histological sections were stained with anti-p16ink4a 
by immunohistochemistry. For the positive stain, the score was based on a scale of - to 3+, as follows: - negative stain; 
1+ less than 25% of positivity and focal distribution; 2+ 26-50% of positivity and focal distribution; and 3+ 50-75% of 
positive cells and diffuse distribution. The evaluation of the intensity score was based on: - negative; 1- low intensity; 
2- moderate intensity; 3- intensive. Results: The results showed no significant differences between the scores (positive 
x intensity) of p16ink4a in normal epithelium, papilloma, and condyloma acuminatum. All benign lesions and normal 
epithelium showed significant differences when compared with the oropharynx squamous cell carcinoma. Relevance: 
There are differences in the expression of p16ink4a between benign HPV-lesions and malignant HPV-lesions.
 DESCRIPTORS | HPV; Papillomaviridae; p16; Condylomata Acuminata; Neoplasms of Squamous Cell.
 RESUMO | Comparação da marcação de p16ink4a por imuno-histoquímica entre lesões benignas e malignas positivas para HPV • 
Objetivo: Analisar a diferença da marcação imuno-histoquímica de p16inka no epitélio normal, em duas lesões benignas associadas ao 
HPV (papiloma e condiloma acuminado) e uma lesão maligna relacionada ao HPV (carcinoma espinocelular de orofaringe). Material e 
métodos: Cinco mucosas normais, quinze papilomas, quinze condilomas acuminados e quinze carcinomas espinocelulares (CEC) po-
sitivos para HPV foram incluídos neste estudo. Os cortes histológicos foram corados com antip16ink4a por imuno-histoquímica. Para 
a marcação positiva, o escore foi baseado numa escala de - a 3+, sendo: - marcação negativa; 1+ menos do que 25% de positividade e 
distribuição focal; 2+ 26-50% de positividade e distribuição focal; 3+ 50-75% de células positivas e distribuição difusa. A avaliação 
da pontuação da intensidade baseou-se em: - negativo; 1- baixa intensidade; 2- intensidade moderada; 3- intensiva. Resultados: Os 
resultados não mostraram diferenças significativas entre os escores (intensidade x positivo) de p16ink4a do epitélio normal, papiloma 
e condiloma acuminado. Todas as lesões benignas e o epitélio normal mostraram diferenças significativas quando comparadas com o 
CEC de orofaringe. Relevância: Há diferenças na expressão de p16ink4a entre lesões benignas e malignas positivas para HPV.
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INTRODUCTION
Human papilloma virus (HPV) is a DNA virus 
of the Papillomaviridae family with approximately 
7900 base pairs. There are over 150 different types 
divided into low-risk (e.g. HPV6 and HPV11) and 
high-risk (e.g. HPV16 and HPV18) HPV. Oral HPV 
transmission is not fully understood and assump-
tions include a subclinical infection, vertical trans-
mission, and horizontal transmission.1 Horizontal 
transmission seems to be the most common route, 
including sexual transmission (orogenital contact). 
The self-inoculation virus from other skin sites or 
anogenital contact is also considered.2 The infec-
tion occurs in proliferating cells (basal cells) of a 
stratified squamous epithelium through micro-
wounds.3 After the infection, the HPV genome can 
integrate in the nucleus as episome and replicate in 
synchrony with the host cellular DNA replication.4
The HPV genome has early genes, whose pri-
mary function is the episomal replication, and late 
genes, which encode the proteins of viral capsid. 
The early genes are divided into E1 to E7 and late 
ones into L1 / L2. The products of E1 and E2 genes 
are more specifically related to regulation of tran-
scription and replication of the viral proteins.5,6
When there is integration of viral genome into 
the host cell genome, the genes may be altered or 
eliminated, leading to uncontrolled transcription of 
E6 and E7.1 Such oncoproteins are capable of inter-
fering with important mechanisms controlling cell 
cycle and apoptosis and maintenance of chromo-
somal stability, deregulating the cell cycle control 
and inducing the cells into the S phase.3,7 It is be-
lieved that tumor cells result from the deregulation 
of two major cell cycle control pathways: the p53 
pathway and pRB pathway.8
The cell cycle is controlled by cyclins, cyclin 
dependent kinases (CDKs), and their inhibitors. 
There are two main inhibitor groups: Cip / Kip 
(p21, p27, and p57) and INK / ARF (p16 and p14).9 
These groups function as tumor suppressors and 
are often altered in tumors. These proteins bind to 
the complex cyclin / inactivate CDK and thus stop 
the cell cycle. p16ink4a is a protein encoded by the 
CDKN2A gene and acts as a tumor suppressor. P16 
inhibits CDK4 (cyclin-dependentkinase 4), an im-
portant protein kinase during the G1 phase of the 
cell cycle. This kinase is responsible for the phos-
phorylation of retinoblastoma (Rb) gene, a tumor 
suppressor.10 Mutations in CDK4 and changes of 
p16 and Rb may be present in carcinomas, partic-
ularly cancers associated with HPV. High-risk E7 
binds to and inactivates Rb, leading to an upregula-
tion of p16. For this reason, the overexpression of 
this protein is target for identifying HPV positive 
cases.11 We aim to analyze the difference between 
p16inka immunostaining in normal epithelium, 
two benign HPV-related lesions (papilloma and 
condyloma acuminatum), and one malignant HPV-
related lesion (oropharynx carcinoma).
MATERIAL AND METHODS
Tissue samples
Ethics approval was obtained from the Human 
Research Ethics Committee (Protocol number: 
10641412.2.0000.0075). Oral HPV-related dis-
eases, diagnosed at the Oral Pathology Diagnostic 
Service of the School of Dentistry of University of 
São Paulo, were retrieved and fifteen papilloma, 
fifteen condyloma acuminatum, and fifteen HPV-
positive oropharynx squamous cell carcinomas 
(OSCCs) were included in this study. Five nor-
mal oral mucosas were used as control. The HPV-
associated OSCCs were chosen based in the intense 
positivity of p16ink4a, overexpression in more than 
70% of the cells12 and with positive cytoplasm and 
nucleus. The OSCCs demonstrating weak or no 
positivity were excluded from this study. The his-
tological sections were first stained with H&E and 
reviewed by two observers. Then, the material was 
used for the IHQ.
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Immunohistochemistry for p16ink4a
Three-micrometer (3 mm) serial sections from 
formalin-fixed paraffin-embedded blocks were ob-
tained and mounted on poly-L-lysine-coated glass 
slides. Immunostaining was performed by the 
linked streptavidin-biotin horseradish peroxidase 
technique (LSAB-HRP) (Universal LSAB®+ Kit/
HRP, DAKO Carpinteria, CA, USA). The samples 
were deparaffinized in xylene followed by hydra-
tion in descending ethanol grades and then treated 
with 0.3% H2O2 and 100% methanol for 15 minutes 
to quench endogenous peroxidase. Antigen retriev-
al was performed by heating specimens for 30 min-
utes at 95oC in sodium citrate. The sections were 
incubated overnight at 4°C with primary monoclo-
nal anti-p16ink4a antibody (1:1000; Abcam 54210, 
clone2D9A12, Cambridge, MA, USA). After three 
washes with Tris buffer, the slides were treated 
with biotinylated species-specific secondary an-
tibodies and streptavidin-biotin enzyme reagent 
(Universal LSAB®+ Kit/HRP, DAKO Carpinteria, 
CA, USA). The color was developed with 3,3’-di-
aminobenzidine tetrahydrochloride chromogen so-
lution (Liquid Dab+ Substrate-Chromogen System, 
Dako, Carpinteria, CA, USA). Sections were coun-
terstained with Mayer’s haematoxylin (Sigma-
Aldrich, St. Louis, MO, USA). Rat’s liver was used 
as a positive control. The results were evaluated 
separately by three investigators.
Immunohistochemistry analysis
For the evaluation of the p16INK4a immu-
nostaining, a semi-quantitative analysis was 
performed using the scoring method for both 
intensity and positivity. Five randomly chosen 
areas were selected and analyzed in conven-
tional light microscope (Olympus CH2 Olympus 
Optical Co. Ltd., Japan) with 400x magnifica-
tion. An analysis of expression of p16INK4a was 
made based on the intensity distribution and on 
the proportion of cells positive for this marker. 
Immunoreactivity was classified by a semi-quan-
titative score for both positivity and intensity of 
staining and the results were multiplied (positive 
x intensity).13 For the positive stain, the score was 
based on a scale of - to 3+, as follows: - negative 
stain; 1+ less than 25% of positivity and focal 
distribution; 2+ 26-50% of positivity and focal 
distribution; and 3+ 51-75% of positive cells and 
diffuse distribution; 4+ ≥76% of positive and dif-
fuse distribution.14 The evaluation of the intensity 
score was based on: - negative; 1- low intensity; 
2- moderate intensity; 3- intensive. The nuclear 
and cytoplasm stain analysis were scored as posi-
tive or negative stain.
Statistical analysis
The data were analyzed using the GraphPad 
Prism 6.0 software (GraphPad Software Inc., San 
Diego, CA, USA). The results were analyzed first by 
the D’Agostino-Pearson omnibus test of normal-
ity. Results were not parametric, therefore we used 
Kruskal-Wallis test and Dunn’s post-hoc test.
RESULTS
p16ink4a immunoscore was analyzed accord-
ing to intensity, immunostain and distribution, and 
nuclear and cytoplasmic stain. The number of cases 
showing each score from samples of normal epi-
thelium, papilloma, condyloma acuminatum, and 
oropharynx squamous cell carcinoma are shown in 
Table 1.
The reason for intensity and distribution analy-
sis is that the positive staining of p16 is present and 
diffuse in all sections, but intensity was noticed to 
be different in each lesion group (Figure 1).
Despite papilloma showing a diffuse stain of 
p16ink4a, the intensity was low, especially when 
compared to squamous cell carcinoma of the oro-
pharynx, which also shows scattered positive cells, 
but with a strong intensity (nucleus and cytoplasm) 
(Figure 1).
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The results showed no significant differenc-
es between the scores (positive x intensity) of 
p16ink4a in normal epithelium (Figure 1A), pap-
illoma (Figure 1B), and condyloma acuminatum 
(Figure 1C). Hence, normal mucosa and benign 
lesions showed significant differences in p16ink4a 
staining when compared with the oropharynx 
squamous cell carcinoma (Figure 1D).
The differences of p16ink4a immunostaining 
(intensity x distribution) between normal mucosa, 
benign, and malignant HPV-related lesions are 
shown in Figure 2.
DISCUSSION
The presence of HPV DNA in a tissue, by itself, 
does not mean that it will induce cancer. There are 
hundreds of different types of HPV, which are di-
vided into low-risk and high-risk. Only the DNA of 
high-risk HPV, transcribed, which demonstrates to 
be active, has clinical and biological relevance in 
the origin of HPV-OSCC.15 This is represented when 
HPV induces molecular changes resulting in malig-
nant transformation.
p16-IHC has been used to detect high-risk 
HPV because of its sensitivity and because it does 
not only indicate the presence of HPV but also its 
activity, since the overexpression of p16 is caused 
by HPV oncoproteins.12,14 In situ hybridization 
technique is a less sensitive method than PCR for 
HPV DNA detection, but more specific than p16 
immunostaining in the detection of HPV in car-
cinomas.7 But some authors believe that conven-
tional HPV ISH nonspecific background is com-
mon and the test lacks sensitivity,14,16 as well as it 
Table 1 | P16ink4a expression patterns in normal mucosa, papilloma, condyloma acuminatum, and oropharynx squamous cell carcinoma.
P16ink4a Intensity P16ink4a Stain Nuclear Stain Cytoplasmic Stain
1 2 3 0 +1 +2 +3 +4 + or - + or -
Normal (5) 5 0 0 0 1 2 0 1 + -
Papilloma (15) 7 7 1 0 6 5 0 4 + -
Condyloma(15) 2 10 3 0 2 3 1 9 + -
OPSCC (15) 0 0 15 0 0 0 1 14 + +
Figure 2 |  Comparison of p16ink4a  immunostaining between 
normal mucosa,  benign,  and malignant  HPV-related  lesions:  OP-
SCC  indicating  significant  differences when  compared  to  normal 
mucosa, papilloma, and condyloma (*p<0.05; ****p<0.0001).
Figure 1 |  p16ink4a  immunohistochemistry  stain.  A.  Normal 
epithelium; B. Papilloma; C. Condyloma; D. Oropharynx squamous 
cell carcinoma.
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is more expensive than IHC. Thus, the use of IHC 
is preferable.14
HPV interacts into the host genome and ex-
presses the replication transcription factors E2, 
E6, and E7 oncoproteins, which repress transcrip-
tion factors.3
Both low-risk and high-risk express E6 and E7, 
but, in the low-risk, E7 does not strongly affect the 
centrosome homeostasis. Still in the high-risk, E6 
and E7 squeal the cell centrosome and cause mi-
totic abnormalities.17 Also, in low-risk HPV, E6 and 
E7 do not immortalize keratinocytes in vitro, as 
they do in high-risk.18 Other studies show differ-
ences between low and high-risk E6 and E7 and 
demonstrate that even though both, low and high-
risk oncoproteins, are capable of binding to p53 
C-terminus, only high-risk E6 oncoproteins are ca-
pable of destroying p53.19
High-risk E6 binds to and inactivates p53, 
leading to its degradation. The degradation of this 
important tumor suppressor alters the cell cycle, 
leading to a malignant transformation. Also, high-
risk E7 binds to another tumor suppressor, reti-
noblastoma (Rb). Once it binds to Rb, it releases 
the E2F transcription factor, leading it from G1 to 
S cell cycle phases. Low levels of Rb lead to over-
expression of p16. Therefore, the finding of over-
expression of p16 has been associated with the 
presence of HPV in its active form. The use of this 
marker is very helpful, especially because carcino-
mas of head and neck related to tobacco showed 
loss of p16 expression.20-23 However, low-risk E7 
binds to Rb but fails to degrade it. Giarrè et al.24 
showed that HPV16 E7 subverts G1-S capture and 
that HPV1 E7 is less efficient in overcoming G1 cell 
cycle,24 consequently it should not overexpress 
p16, as showed in this study.
Thus, normal epithelium, negative for HPV, and 
oral benign low-risk HPV lesions such as papilloma 
and condyloma, were expected not to show strong 
expression of p16ink4a, as seen in our results. It 
is known that condyloma acuminatum may pres-
ent low-risk and high-risk HPV,25,26 and possibly 
may release proteins that increase p16 expres-
sion, as seen in our cases, which showed a strong 
positive nucleus but not cytoplasmatic expression. 
According to this study, there were no significant 
differences between the two benign lesions used 
and normal epithelium, even if some samples 
showed nuclear staining for p16. Thus, the presence 
of HPV cannot be assured only by the positivity to 
p16ink4a-IHC in those cases.
The correlation of p16 with high-risk HPV has 
caused great debates, since different studies used 
different IHC methods and antibodies, and they 
could cause false-positive or false-negative results. 
But, based in a systematic review,12 we considered 
the correlation between p16-IHC and HPV in cases 
showing p16 overexpression in more than 70% of 
the cells and with cytoplasm and nucleus with posi-
tive stain. Thus, our results showed a significant 
difference between HPV-OSCC and HPV-benign 
lesions, as well as  normal epithelium. OPSCC was 
the only group that showed both cytoplasmatic and 
nuclear stain. The other groups showed only nucle-
ar stain.
In conclusion, we observed differences in the 
expression of p16ink4a between benign HPV-
lesions and malignant HPV-lesions.
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